Fig. 6. emeA-lacZ marks the mesodermal Eve lineage. (A-F) Double labeling for Eve (green) and ß-Gal (marking emeA-lacZ expression in red) of two hemisegments in stage 13 embryos. (A) In wild type, emeA-lacZ labels the two EPCs, as well as both the DA1 and DO2 muscle founders. (B) In embryos with ectopic dap in the mesoderm, the number of EPCs is reduced to one per hemisegment, but the DA1 and DO2 founders are unaffected. (C) In CycA mutants, no EPCs are specified but both muscle founder cells are unaffected. (D) In numb mutants, the number of EPCs is increased from 2 to average 3.6 per hemisegment with loss of both muscle founders. (E) eme-specific overexpression of numb causes a twofold increase in the number of DA1 and DO2 founders concomitantly with a loss of EPCs. (F) eme-specific overexpression of N(icd), as in numb mutants, causes a loss of the eve muscle founder and a doubling of EPCs.